XTL Biopharmaceuticals Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of February 2026 for XTL Biopharmaceuticals Ltd., a foreign private issuer headquartered in Herzliya, Israel. The report details a corporate governance event regarding an Extraordinary General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a procedural update regarding a shareholder meeting and contains no financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The only material event disclosed is the procedural adjournment of a shareholder meeting.
Outlook, Risks, and Unusual Items
Shareholder Meeting Adjournment: On February 17, 2026, the Company convened an Extraordinary General Meeting of Shareholders. The meeting was adjourned for one week due to a lack of quorum.
Reconvened Meeting Details: The meeting is scheduled to be reconvened on Tuesday, February 24, 2026, at 4:00 p.m. Israel time. The location is the offices of the Company's attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.
Key Facts for Investor Verification
- Verify the agenda items for the Extraordinary General Meeting scheduled for February 24, 2026.
- Confirm whether the reconvened meeting achieves a quorum and if any resolutions are passed.
- Note that this filing contains no financial performance data; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.